Robert J. Gray, PhD

Robert J. Gray, PhD

Researcher

Contact Information

Office Phone Number

(617) 632-2446

Fax

(617) 632-2444

Biography

Robert J. Gray, PhD

Dr. Gray completed his PhD in statistics at Oregon State University in 1982. After joining DFCI as a postdoctoral fellow, he became a faculty member in 1984. He has worked extensively on methods for the analysis of censored failure-time data and competing-risks problems. He has also been a statistician with the Eastern Cooperative Oncology Group, and in 2001 became the head of the ECOG Statistical Center.

Researcher

Physician

Professor of Biostatistics, Harvard T.H. Chan School of Public Health

Research

    Clinical Trials and Statistical Methods for Cancer Research

    Our major research activities involve the design and analysis of clinical trials and the study of related statistical issues. The Statistical Center for the Eastern Cooperative Oncology Group, headed by Dr. Gray, is involved in dozens of studies which often include biological correlative endpoints and quality-of-life evaluations, as well as evaluations of primary efficacy. Current research interests include methods of adjustment for treatment noncompliance, design and analysis of studies with competing-risks endpoints, methods for analyzing correlated failure-time data, dependent censoring (related to incomplete follow-up of disease status), issues of interim analysis of clinical data, and analysis of high-dimensional laboratory data.Correlated failure-time data can arise in a variety of settings, such as multicenter clinical trials, in which patient outcomes may vary by center. Correlated data methods for estimating the effects of baseline characteristics on the prognosis of cancer patients have been developed. These methods generally involve solving estimating equations, which depend on families of weight functions that can be used to incorporate information on the degree and structure of the dependence in the data. In theory, incorporating such information should improve prognostic estimates of effects, but attempts to do so have not been very successful. We have investigated the magnitude of the gains possible in both linear failure-time models and proportional hazards models. From this work, we have developed new approaches for estimation using linear-models that closely approximate the weight functions that minimize the sampling variation of the estimated effects. The presence of competing causes of failure for the primary end point in a clinical trial is another problem that makes interpretation and analysis difficult. For example, in studies of treatment for elderly patients with breast cancer, the primary end point might be prolonging time to disease recurrence or time to breast cancer mortality. But some patients may develop other diseases and die without experiencing failure of the primary end point for the study, thus creating complications for the statistical analysis. Related problems can occur in examining the effect of radiotherapy on controlling disease at the site where it is applied, when there are competing risks of disease at other sites. We have developed models that directly estimate the effect of factors on the probability of observable events in these competing-risks settings, and have successfully applied these models to local failure rates in breast cancer patients. Progression-based failure-time endpoints in clinical trials require adherence to a regular schedule of disease evaluations. When protocol treatment is terminated without documented progression, the disease evaluation schedule may not be followed, or results of evaluations may not be reported. Patients withdrawn from study without documented progression often have different risk for progression than those continuing on study, and the lack of further information on disease status for these patients potentially biases statistical analyses. In current work, we are investigating the potential impact of these biases and developing methods for exploring the sensitivity of analyses to incomplete follow-up on disease status.

    Research Departments

    Publications

      • The New NCI Precision Medicine Trials. Clin Cancer Res. 2023 Aug 02. View in: Pubmed

      • The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023 Jun; 29(6):1349-1357. View in: Pubmed

      • Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clin Cancer Res. 2023 04 14; 29(8):1477-1483. View in: Pubmed

      • National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clin Cancer Res. 2023 04 14; 29(8):1412-1422. View in: Pubmed

      • Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precis Oncol. 2023 04; 7:e2200421. View in: Pubmed

      • Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. J Clin Oncol. 2023 04 10; 41(11):2020-2028. View in: Pubmed

      • Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. JCO Precis Oncol. 2022 07; 6:e2200165. View in: Pubmed

      • Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2022 04 01; 8(4):579-586. View in: Pubmed

      • Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. Blood Cancer J. 2022 04 01; 12(4):53. View in: Pubmed

      • Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ Precis Oncol. 2022 Mar 01; 6(1):13. View in: Pubmed

      • Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 05 10; 40(14):1552-1561. View in: Pubmed

      • Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 02; 6:e2100424. View in: Pubmed

      • Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022 Jan 11; 8(1):3. View in: Pubmed

      • Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. Cancer. 2021 12 15; 127(24):4546-4556. View in: Pubmed

      • A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 01 15; 28(2):271-278. View in: Pubmed

      • Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer. 2022 Feb 01; 128(3):536-546. View in: Pubmed

      • Reclassifying stroke lesion anatomy. Cortex. 2021 12; 145:1-12. View in: Pubmed

      • Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021 Jun 17. View in: Pubmed

      • Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. Ann Oncol. 2021 Aug; 32(8):1068. View in: Pubmed

      • Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. J Natl Cancer Inst. 2021 04 06; 113(4):390-399. View in: Pubmed

      • Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. Cancer. 2021 07 15; 127(14):2545-2552. View in: Pubmed

      • Reply to K. Ando et al. J Clin Oncol. 2021 06 10; 39(17):1947-1948. View in: Pubmed

      • Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 06 01; 27(11):2996-3004. View in: Pubmed

      • Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol. 2021 02 01; 7(2):271-278. View in: Pubmed

      • Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. J Clin Oncol. 2021 02 20; 39(6):557-564. View in: Pubmed

      • Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894. View in: Pubmed

      • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029. View in: Pubmed

      • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020 11 20; 38(33):3895-3904. View in: Pubmed

      • Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 07 20; 38(21):2407-2417. View in: Pubmed

      • Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. 2020 06 10; 38(17):1875-1886. View in: Pubmed

      • Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 03 01; 6(3):367-374. View in: Pubmed

      • Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clin Cancer Res. 2020 04 15; 26(8):1812-1819. View in: Pubmed

      • Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 Nov; 30(11):1821-1830. View in: Pubmed

      • Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222. View in: Pubmed

      • Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 11 01; 30(11):1821-1830. View in: Pubmed

      • Noninferiority trials with nonadherence to the assigned randomized treatment. Clin Trials. 2019 12; 16(6):673-681. View in: Pubmed

      • Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz062. View in: Pubmed

      • Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz050. View in: Pubmed

      • Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz049. View in: Pubmed

      • TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. J Clin Oncol. 2019 07 20; 37(21):1841-1842. View in: Pubmed

      • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405. View in: Pubmed

      • Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 03 01; 37(7):559-569. View in: Pubmed

      • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1360-1369. View in: Pubmed

      • Pragmatic approaches to address expansion cohort design. Cancer. 2018 08; 124(16):3290-3292. View in: Pubmed

      • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):111-121. View in: Pubmed

      • E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018; 4:1. View in: Pubmed

      • A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer. 2017; 3:42. View in: Pubmed

      • High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. JCO Precis Oncol. 2017; 1. View in: Pubmed

      • The EFCR Approach and the Radial Septum-Understanding the Anatomy and Improving Volar Exposure for Distal Radius Fractures: Imagine What You Could Do With an Extra Inch. Tech Hand Up Extrem Surg. 2016 Dec; 20(4):155-160. View in: Pubmed

      • Reply to C. Shah et al. J Clin Oncol. 2016 05 20; 34(15):1824-5. View in: Pubmed

      • Estimating treatment effect in a proportional hazards model in randomized clinical trials with all-or-nothing compliance. Biometrics. 2016 09; 72(3):742-50. View in: Pubmed

      • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373(21):2005-14. View in: Pubmed

      • Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015 Nov 20; 33(33):3938-44. View in: Pubmed

      • Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20; 32(27):2959-66. View in: Pubmed

      • Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol. 2014 Sep 10; 32(26_suppl):36. View in: Pubmed

      • Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8. View in: Pubmed

      • Reply to S. Goteti et al. J Clin Oncol. 2014 Mar 10; 32(8):856. View in: Pubmed

      • Marker Sequential Test (MaST) design. Clin Trials. 2014 Feb; 11(1):19-27. View in: Pubmed

      • An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials. 2013 Oct; 10(5):754-60. View in: Pubmed

      • A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15; 105(10):701-10. View in: Pubmed

      • Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol. 2013 Sep 01; 31(25):3158-61. View in: Pubmed

      • Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9. View in: Pubmed

      • Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood. 2013 Jan 03; 121(1):156-8. View in: Pubmed

      • Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013 Mar 15; 119(6):1140-8. View in: Pubmed

      • TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):751-7. View in: Pubmed

      • Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92. View in: Pubmed

      • Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials. Clin Trials. 2012 Apr; 9(2):155-63. View in: Pubmed

      • The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012 Sep 01; 106(3):254-9. View in: Pubmed

      • The impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy. J Clin Oncol. 2011 Sep 20; 29(27_suppl):96. View in: Pubmed

      • Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011 Nov 15; 17(22):7194-203. View in: Pubmed

      • Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials. 2011 Oct; 8(5):591-600. View in: Pubmed

      • Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2012 Feb; 109(4):596-602. View in: Pubmed

      • When bad things happen to good studies. J Clin Oncol. 2011 Sep 10; 29(26):3497-9. View in: Pubmed

      • Effect of lattice structure on energetic electron transport in solids irradiated by ultraintense laser pulses. Phys Rev Lett. 2011 May 06; 106(18):185004. View in: Pubmed

      • An audit strategy for progression-free survival. Biometrics. 2011 Sep; 67(3):1092-9. View in: Pubmed

      • Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011 Jan; 6(1):103-8. View in: Pubmed

      • Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47. View in: Pubmed

      • Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010; 12(3):R26. View in: Pubmed

      • Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics. 2010 Oct; 11(4):676-92. View in: Pubmed

      • A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials. 2010 Jun; 7(3):197-208. View in: Pubmed

      • Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7693-7700. View in: Pubmed

      • Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Nov 10; 27(32):5319-24. View in: Pubmed

      • Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009 Dec 10; 27(35):5958-64. View in: Pubmed

      • Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009 Oct 20; 27(30):4966-72. View in: Pubmed

      • Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol. 2009 Sep 01; 27(25):e82-3; author reply e84. View in: Pubmed

      • Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009 May 15; 69(10):4184-91. View in: Pubmed

      • Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med. 2008 Nov 29; 27(27):5709-24. View in: Pubmed

      • Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5. View in: Pubmed

      • Weighted analyses for cohort sampling designs. Lifetime Data Anal. 2009 Mar; 15(1):24-40. View in: Pubmed

      • Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 01; 26(25):4063-71. View in: Pubmed

      • Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008 Jul 15; 14(14):4368-71. View in: Pubmed

      • Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clin Cancer Res. 2008 Jun 01; 14(11):3427-33. View in: Pubmed

      • Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. J Clin Oncol. 2008 May 20; 26(15_suppl):557. View in: Pubmed

      • Sensitivity analysis of progression-free survival with dependent withdrawal. Stat Med. 2008 Apr 15; 27(8):1180-98. View in: Pubmed

      • Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008 Mar 01; 14(5):1407-12. View in: Pubmed

      • Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5. View in: Pubmed

      • Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol. 2007 Nov 01; 25(31):5019-23. View in: Pubmed

      • Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007 May 20; 25(15):2127-32. View in: Pubmed

      • Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol. 2007 May 20; 25(15):2122-6. View in: Pubmed

      • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14; 355(24):2542-50. View in: Pubmed

      • Bayesian modeling approach to examining heterogeneity in censored survival analysis. Biometrics. 2006 Jun; 62(2):623; author reply 623-4. View in: Pubmed

      • Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9. View in: Pubmed

      • A method for analyzing disease-specific mortality with missing cause of death information. Lifetime Data Anal. 2006 Mar; 12(1):35-51. View in: Pubmed

      • Generalized rank tests for replicated microarray data. Stat Appl Genet Mol Biol. 2005; 4:Article3. View in: Pubmed

      • Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72. View in: Pubmed

      • Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res. 2004 Feb 15; 10(4):1206-11. View in: Pubmed

      • Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2003 Oct; 42(1):79-86. View in: Pubmed

      • Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26. View in: Pubmed

      • Weighted estimating equations for linear regression analysis of clustered failure time data. Lifetime Data Anal. 2003 Jun; 9(2):123-38. View in: Pubmed

      • Optimal weight functions for marginal proportional hazards analysis of clustered failure time data. Lifetime Data Anal. 2002 Mar; 8(1):5-19. View in: Pubmed

      • Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001; (30):44-51. View in: Pubmed

      • Estimation of regression parameters and the hazard function in transformed linear survival models. Biometrics. 2000 Jun; 56(2):571-6. View in: Pubmed

      • On tests for group variation with a small to moderate number of groups. Lifetime Data Anal. 1998; 4(2):139-48. View in: Pubmed

      • Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997 Dec; 64(6):1686-93. View in: Pubmed

      • Spline-based tests in survival analysis. Biometrics. 1994 Sep; 50(3):640-52. View in: Pubmed

      • A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. Biometrics. 1994 Mar; 50(1):244-53. View in: Pubmed

      • Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics. 1990 Mar; 46(1):93-102. View in: Pubmed

      • A linear rank test for use when the main interest is in differences in cure rates. Biometrics. 1989 Sep; 45(3):899-904. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue CLS 11002 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue CLS 11002 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Discovery & Insights